The stock hit a record high of Rs 2,840 on 22 April 2021. In the past one year, the stock has declined 43.76% while the benchmark Sensex has added 22.33% during the same period.

On the technical front, the stock's RSI (relative strength index) stood at 65.75. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.

The stock was trading above its 50-day simple moving average (SMA) placed at 1174.65. It was still below its 100-day and 200-day SMA placed at 1401.18 and 1581.74, respectively.

Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs. It provides solutions across the full range of the pharmaceutical industry's chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life-cycle, as well as commercial launch.

On a consolidated basis, net profit of Neuland Laboratories declined 51.61% to Rs 12.94 crore on 3.64% decline in net sales to Rs 236.47 crore in Q3 December 2021 over Q3 December 2020.